Tag: OVERTURE study
Cognito announces OVERTURE II results indicating durable effects of Spectris treatment...
Cognito Therapeutics has announced treatment results from OVERTURE II—an open-label extension (OLE) study of Spectris, the company’s potential disease-modifying therapy for the treatment of...
Cognito announces 18-month data showing durability of gamma sensory stimulation for...
Cognito Therapeutics has announced that continued active treatment with the company’s gamma sensory stimulation technology in the Phase 2 OVERTURE open label extension (OLE)...
Cognito presents MRI data showing efficacy of non-invasive gamma stimulation therapy...
Cognito Therapeutics has announced “robust, lobe-specific” changes in white matter volume and myelination in Alzheimer’s disease patients following six months of non-invasive gamma stimulation...
